EF Hutton initiates coverage today on CLNN with a $13 price target. And HC Wainwright has reiterated a $15 price target twice in recent days. And CLNN has reported positive trial results in recent weeks. Other than there appear to be a bunch of pesky shorters involved, this seems like a gift down here. Also, CLNN will be presenting in the upcoming Roth's 35th annual healthcare conference.
News 
Market Data 
Discover 
